8 May 2014
On May 8, 2014, AstraZeneca will join the global community in recognizing World Ovarian Cancer Day (WOCD), designed to raise awareness for ovarian cancer – a disease which still ranks fifth in cancer deaths among U.S. women and claims more deaths than any other female cancer of the reproductive system.
AstraZeneca Recognizes 2nd World Ovarian Cancer Day
n line with this year’s theme, AstraZeneca is calling on people to take five minutes out of their day to share five facts about ovarian cancer with five friends or family members. We want as many people as possible to sign the WOCD pledge at www.ovariancancerday.org and help spread this message.
A woman’s risk for developing ovarian cancer and her subsequent prognosis are influenced by several factors, including age, early diagnosis, and family history. Women with BRCA mutations are at a heightened risk of developing ovarian cancer and it is estimated that as many as 40 percent of women with the genetic mutation will go on to be diagnosed with the disease in their lifetime. At AstraZeneca, we recognize the severity of the unmet treatment need for women living with ovarian cancer.
AstraZeneca remains committed to expanding our more than 30-year history in oncology through continued gynecologic cancer research. As we look forward, we consider it important to engage with the ovarian cancer community. Ultimately, our drive to work towards solutions in the field of oncology is fueled by our dedication to meet the shifting needs of patients – wherever they may be in their journey.
We look forward to a day on which we can celebrate all of the unmet needs in ovarian cancer being met. Until then, we recognize the importance of this day as an opportunity to raise awareness.